Completed PHASE2 INTERVENTIONAL 1-arm NCT03652857

Apatinib Combined With Vinorelbine for Non-driver Gene Mutation Non-small Cell Lung Cancer

the Effectiveness and Safety Study on Apatinib Combined With Vinorelbine Used for Driver Gene Mutation Negative Third-line and Third-line Post Progression Advanced Non-small Cell Lung Cancer

Sponsor: Yongchang Zhang

Conditions Advanced Non Small Cell Lung Cancer

Interventions Apatinib Combined With Vinorelbine

Updated 6 times since 2018 Last updated: Feb 12, 2020 Started: Jan 1, 2017 Primary completion: Nov 30, 2018 Completion: Dec 31, 2019

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Advanced Non Small Cell Lung Cancer and is currently completed. Yongchang Zhang leads this study, which shows 6 recorded versions since 2017 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Mar 2020 — Jan 2021 [monthly]

Completed PHASE2

Status: Recruiting → Completed
Feb 2019 — Mar 2020 [monthly]

Recruiting PHASE2

Phase: PHASE1 → PHASE2

▶ Show 1 earlier version

Sep 2018 — Feb 2019 [monthly]

Recruiting PHASE1

First recorded

Jan 2017

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Yongchang Zhang

Data source: Hunan Province Tumor Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Changsha, China